A Phase 3 interventional study of Evolocumab and Placebo to Evolocumab in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-20.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 11th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 5th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 11th largest by enrollment, is one of 7 that started in 2013, is one of 11 in phase 3, and was the 5th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Ezetimibe
Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Placebo to Evolocumab · Drug: Ezetimibe
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Placebo to Ezetimibe
Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Placebo to Ezetimibe
Subcutaneous injection
Also known as: AMG 145, Repatha
Subcutaneous injection
Tablet for oral administration
Also known as: Zetia
Tablet for oral administration
Percent Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame: Weeks 10 and 12
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame: Week 12
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Lipoprotein (a) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12
Time frame: Baseline and Week 12
Men and women ≥ 18 to ≤ 80 years of age who have tried at least 2 statins and were unable to tolerate any dose or increase in statin dose due to muscle-related side effects were eligible for this study. The first participant was enrolled on 24 January 2013 and the last participant enrolled on 29 August 2013.
| Milestone | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Started | 51 | 51 | 103 | 102 |
| Completed | 45 | 50 | 94 | 101 |
| Not completed | 6 | 1 | 9 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 1 |
| Withdrew: Decision by sponsor | 5 | 0 | 8 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at Week 12 | -18.08 ± 2.52 | -15.05 ± 2.13 | -56.14 ± 1.91 | -52.60 ± 1.58 |
| mg/dL | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -39.1 ± 5.1 | -33.0 ± 4.5 | -105.4 ± 3.9 | -103.6 ± 3.4 |
| mg/dL | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -36.2 ± 5.4 | -30.2 ± 4.7 | -106.0 ± 4.1 | -99.0 ± 3.5 |
| percentage of participants | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L) | 2.0 (0.4 to 10.5) | 0.0 (0.0 to 7.3) | 45.5 (36.2 to 55.2) | 42.0 (32.8 to 51.8) |
| percentage of participants | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12 | 2.0 (0.4 to 10.7) | 0.0 (0.0 to 7.9) | 50.0 (40.3 to 59.7) | 37.5 (28.5 to 47.5) |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12 | -17.18 ± 2.15 | -14.54 ± 1.86 | -48.72 ± 1.64 | -49.13 ± 1.40 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | -16.53 ± 2.30 | -13.16 ± 1.93 | -48.62 ± 1.74 | -46.15 ± 1.43 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | -13.67 ± 2.15 | -11.02 ± 2.21 | -45.88 ± 1.68 | -46.01 ± 1.65 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | -12.95 ± 2.32 | -9.97 ± 2.34 | -45.81 ± 1.79 | -43.07 ± 1.73 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12 | -13.44 ± 2.14 | -11.20 ± 2.16 | -40.83 ± 1.65 | -41.14 ± 1.62 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12 | -14.13 ± 2.30 | -9.92 ± 2.34 | -40.42 ± 1.75 | -38.57 ± 1.73 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12 | -13.00 ± 2.27 | -11.94 ± 2.56 | -47.86 ± 1.77 | -48.31 ± 1.92 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12 | -13.14 ± 2.47 | -11.37 ± 2.71 | -47.66 ± 1.90 | -45.51 ± 2.01 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12 | -2.30 ± 3.36 | 1.55 ± 4.01 | -26.20 ± 2.64 | -23.72 ± 2.97 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 | -1.74 ± 3.58 | 5.81 ± 5.10 | -27.03 ± 2.78 | -22.07 ± 3.66 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | -3.74 ± 3.88 | -0.32 ± 4.65 | -6.32 ± 2.94 | -6.73 ± 3.44 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | -5.47 ± 4.25 | 2.16 ± 5.52 | -3.88 ± 3.18 | -2.53 ± 3.98 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12 | 0.33 ± 1.98 | 1.44 ± 2.03 | 5.48 ± 1.51 | 7.18 ± 1.51 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 1.77 ± 2.22 | 1.64 ± 2.22 | 5.34 ± 1.67 | 6.47 ± 1.63 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12 | -5.76 ± 3.80 | -2.93 ± 4.41 | -7.60 ± 2.89 | -6.46 ± 3.21 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12 | -5.49 ± 4.05 | -2.25 ± 5.11 | -6.16 ± 3.08 | -2.18 ± 3.60 |
| percent change | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -19.21 ± 2.40 | -16.62 ± 2.03 | -56.11 ± 1.83 | -55.31 ± 1.53 |
Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe (Q2W) | — | 1/51 (2%) | 20/51 (39.2%) |
| Ezetimibe (QM) | — | 3/51 (5.9%) | 29/51 (56.9%) |
| Evolocumab Q2W | — | 5/103 (4.9%) | 28/103 (27.2%) |
| Evolocumab QM | — | 1/102 (1%) | 42/102 (41.2%) |
| Event | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Gastrointestinal motility disorderGastrointestinal disorders | 1/51 | 0/51 | 0/103 | 0/102 |
| Inguinal herniaGastrointestinal disorders | 0/51 | 1/51 | 0/103 | 0/102 |
| Kidney infectionInfections and infestations | 0/51 | 1/51 | 0/103 | 0/102 |
| Spinal decompressionSurgical and medical procedures | 0/51 | 1/51 | 0/103 | 0/102 |
| Cartilage graftSurgical and medical procedures | 0/51 | 0/51 | 0/103 | 1/102 |
| OsteotomySurgical and medical procedures | 0/51 | 0/51 | 0/103 | 1/102 |
| Hepatic enzyme increasedInvestigations | 0/51 | 0/51 | 1/103 | 0/102 |
| Back painMusculoskeletal and connective tissue disorders | 0/51 | 0/51 | 1/103 | 0/102 |
| Bladder transitional cell carcinoma stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/51 | 0/51 | 1/103 | 0/102 |
| LipomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/51 | 0/51 | 1/103 | 0/102 |
| Event | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 7/51 | 11/51 | 7/103 | 9/102 |
| FatigueGeneral disorders | 4/51 | 6/51 | 3/103 | 6/102 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/51 | 1/51 | 2/103 | 12/102 |
| HeadacheNervous system disorders | 3/51 | 6/51 | 4/103 | 12/102 |
| NauseaGastrointestinal disorders | 2/51 | 5/51 | 3/103 | 6/102 |
| DiarrhoeaGastrointestinal disorders | 3/51 | 4/51 | 3/103 | 2/102 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/51 | 1/51 | 5/103 | 8/102 |
| ParaesthesiaNervous system disorders | 1/51 | 4/51 | 0/103 | 2/102 |
| Injection site erythemaGeneral disorders | 0/51 | 3/51 | 2/103 | 2/102 |
| InfluenzaInfections and infestations | 3/51 | 0/51 | 1/103 | 0/102 |
| Age, Continuous(years) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 61.7 ± 10.1 | 60.2 ± 8.7 | 60.5 ± 9.7 | 62.9 ± 10.2 | 61.5 ± 9.8 |
| Sex: Female, Male(Participants) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Female | 27 | 22 | 46 | 46 | 141 |
| Male | 24 | 29 | 57 | 56 | 166 |
| Race/Ethnicity, Customized(participants) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 5 | 1 | 10 |
| Black or African American | 0 | 1 | 3 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| White | 49 | 46 | 94 | 98 | 287 |
| Other | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(participants) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 | 1 | 7 |
| Not Hispanic or Latino | 50 | 49 | 100 | 101 | 300 |
| Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level(participants) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| < 180 mg/dL | 26 | 26 | 52 | 52 | 156 |
| ≥ 180 mg/dL | 25 | 25 | 51 | 50 | 151 |
| Stratification Factor: Baseline Statin Use(participants) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| No | 41 | 42 | 84 | 82 | 249 |
| Yes | 10 | 9 | 19 | 20 | 58 |
| LDL-C Concentration(mg/dL) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 194.7 ± 63.8 | 195.2 ± 51.8 | 192.0 ± 57.0 | 192.2 ± 61.2 | 193.1 ± 58.5 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 231.4 ± 66.0 | 232.9 ± 57.0 | 227.9 ± 56.6 | 222.1 ± 63.2 | 227.4 ± 60.4 |
7 further baseline measures are reported on the registry.
Ran from Jan 2013 to primary completion in Nov 2013, 9 months.
Results were first posted in Dec 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab